Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MDX2301

Other · developed by ModeX Therapeutics, An OPKO Health Company

Phase 1 Most advanced trial
OPK Developer
1 Registered trials

What is MDX2301?

MDX2301 is an agent studied for the prevention of COVID-19, given by intravenous infusion, intramuscular injection, or subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
ModeX Therapeutics, An OPKO Health Company (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07445971 Phase 1 COVID -19 Recruiting OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID -19COVID-19 (Prevention)

More from ModeX Therapeutics, An OPKO Health Company

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.

Follow OPK, the company behind MDX2301

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.